Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Active:	No
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT04729608
Trial Phases:	Phase III	Protocol IDs:	AVB500-OC-004 (primary) GOG-3059 NCI-2021-05984 AXLerate-OC ENGOT OV66
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Aravive, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04729608

Summary

This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of
batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination
with PAC in patients with platinum resistant recurrent ovarian cancer.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.